media – Page 8 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Big news! Johnson & Johnson’s new autoimmune drug nicalimab approved in China

Recently, the NMPA (National Medical Products Administration) announced the launch of Johnson & Johnson’s nicarlimumab injection (trade name: Anliwei® ), for use in combination with conventional therapies to treat adult patients and adolescents older than 12 years with autoantibodies-positive generalized myasthenia gravis (gMG). This marks another significant milestone for nicarlimumab globally, following its FDA approval last April and subsequent approval by the European Commission, and also signifies the arrival of a strong new competitor in the field of precision treatment for gMG in China. In August 2020, Johnson & Johnson announced its acquisition of Momenta Pharmaceuticals for approximately $6.5 billion, with its core objective being this investigational FcRn antibody. On April 30, 2025, nicarlimumab received initial FDA approval in the United States (trade name IMAAVY®) for the treatment of patients aged 12 years and older with positive anti-AChR or anti-MuSK antibodies in generalized myasthenia gravis. Subsequently, the European Commission also ...
- Source: drugdu
- 77
- May 26, 2026
Health & Hygiene Expo

Organiser：Bangladesh Exhibitions Pvt. Ltd. Time：November 5–7, 2026 Address：Plot# 66, Block#C, Umme kulsum Road, Bashundhara R/ A, Dhaka-1229, Dhaka Exhibition hall：International Convention City, Bashundhara Dhaka Product range: Sanitation & Hygiene Solutions | Personal & Household Hygiene | Air & Water Purification Systems | Waste Management & Recycling | Workplace & Industrial Hygiene | Public Health & Safety Equipment | Protective & Safety Gear (PPE) | Healthcare & Health Solutions | Sanitation & Disinfection Equipment | Community Health Solutions About Health & Hygiene Expo： Health & Hygiene Expo Dhaka is the most authoritative health and hygiene exhibition in Bangladesh. Dedicated to showcasing the latest advancements and innovations in the health industry, it is an unmissable event for professionals, experts, and enthusiasts from across the country and around the globe. With over 285 exhibitors currently on board, the expo will deliver a comprehensive and diverse display of the latest products in ...
- Source: drugdu
- 69
- May 26, 2026
Qilu Pharmaceutical’s generic version of “Sinimod tablets” has been approved for marketing, aiming to rival Novartis

Multiple sclerosis (MS) is a severe, lifelong, progressive, and highly disabling autoimmune chronic disease of the central nervous system (CNS). It commonly affects the periventricular region, juxtacortex, optic nerve, spinal cord, brainstem, and cerebellum, exhibiting spatial and temporal dissemination. Incidence and prevalence are correlated with geographic distribution and ethnicity. On May 21, 2026, according to the latest information on the official website of the National Medical Products Administration (NMPA) of China, Qilu Pharmaceutical Co., Ltd. ‘s application for sinimod tablets was approved for marketing. Public information shows that sinimod tablets are a sphingosine-1-phosphate (S1P) receptor modulator used to treat relapsing-remitting multiple sclerosis in adults , including active secondary progressive multiple sclerosis, relapsing-remitting multiple sclerosis, and clinically isolated syndrome. It is worth mentioning that on the same day, Kelun Pharmaceutical’s application for sinimod tablets was also approved for marketing , making both pharmaceutical companies the first generic versions of this drug ...
- Source: drugdu
- 81
- May 25, 2026
Unprecedented! Three domestically produced ustekinumab drugs received approval within two days, completely ending the era of original drug monopoly

From May 21st to 22nd, 2026, the National Medical Products Administration (NMPA) issued a series of major drug approvals, with biosimilars of ustekinumab from three major domestic pharmaceutical companies—Huadong Medicine, Bio-Thera Solutions, and CSPC Pharmaceutical Group—receiving approval for marketing in quick succession , creating an unprecedented surge in approvals in the domestic autoimmune biologics field. Specifically, Huadong Medicine and Bio-Thera Solutions simultaneously obtained approval for Crohn’s disease indications on May 21st, both for intravenous infusion and subcutaneous injection formulations; while CSPC Pharmaceutical Group’s Enyike® officially received approval for plaque psoriasis indications on May 22nd. This round of approvals completely ends the six-year monopoly of the original Johnson & Johnson Stardenafil®, significantly expands the range of autoimmune disease treatment options in China, and brings more affordable and higher-quality domestic treatment options to millions of patients with psoriasis and inflammatory bowel disease in China. The urgent need of millions of patients: a ...
- Source: drugdu
- 92
- May 25, 2026
First! FDA approves Gilead’s liver therapy

On May 22, 2026, the FDA announced accelerated approval for Gilead ‘s Hepcludex (bulevirtide) injection for the treatment of chronic hepatitis D virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis. Screenshot source: FDAThis approval not only marks the official birth of the first treatment for chronic HDV infection in the United States, but also fills a long-standing clinical gap in the field.HDV infection occurs only in individuals infected with hepatitis B virus (HBV), and can take the form of co-infection or superinfection. Compared to HBV infection alone, co-infection with HDV accelerates the progression of liver fibrosis and significantly increases the risk of cirrhosis, hepatocellular carcinoma, and liver disease-related death .Hepcludex was approved based on data from a Phase III clinical trial called MYR301. Results showed that at week 48, patients treated with Hepcludex 8.5 mg once daily had a comprehensive response rate (significantly reduced viral load and ...
- Source: drugdu
- 72
- May 25, 2026
Lunan Pharmaceutical’s Lilin® Bortezomib for Injection has been approved for marketing and is considered to have passed the evaluation

Recently, Lilin® Bortezomib for Injection (specifications: 1.0mg, 3.5mg) produced by Shandong New Era Pharmaceutical Co., Ltd., a subsidiary of Lunan Pharmaceutical Group , was approved for marketing by the National Medical Products Administration and is considered to have passed the consistency evaluation of generic drug quality and efficacy. The approval numbers are: National Drug Approval Number H20264387 and National Drug Approval Number H20264388. The active ingredient in this product is bortezomib, a reversible inhibitor of chymotrypsin-like activity of the 26S proteasome in mammalian cells. It induces tumor cell apoptosis by inhibiting proteasome function, interfering with the ubiquitin-proteasome pathway, and blocking the degradation of key signaling proteins within tumor cells. Preclinical studies have shown its significant inhibitory effect on tumors such as multiple myeloma. When used for multiple myeloma, this product can be combined with melphalan and prednisone (MP regimen) for previously untreated patients who are not suitable for high-dose chemotherapy ...
- Source: drugdu
- 64
- May 25, 2026
its shares surged over 140% at the open, with Northern Light Venture Capital and Gaotejia among its shareholders

Overcoming the challenge of antimicrobial resistance, two world-first products form a dual engine for anti-infection. On May 22, Danuo Pharmaceutical (Suzhou) Co., Ltd. (hereinafter referred to as “Danuo Pharmaceutical”) officially listed on the main board of the Hong Kong Stock Exchange with the stock code 6872.HK. The global offering consisted of 8,856,000 H shares, with an issue price of HK$75.70, raising a total of approximately HK$627 million and net proceeds of approximately HK$558 million. The IPO was jointly sponsored by CITIC Securities (25.870, 0.00, 0.00%) and ABC International. Cornerstone investors included AMR Action Fund, Yuanhe Holdings, Orient Asset Management, and Junsheng Global, who subscribed for a total of approximately 3,082,450 shares, representing 34.81% of the total global offering. The international placement portion of the IPO was oversubscribed by 9.24 times, while the Hong Kong public offering was also highly popular, recording an oversubscription of 9,015 times, ranking second in the ...
- Source: drugdu
- 74
- May 25, 2026
A single-quarter revenue of 4.4 billion! The “King of Nuclear Drugs” ignites precision treatment for prostate cancer

With quarterly sales of $642 million (approximately RMB 4.4 billion), a 70% year-on-year increase, Pluvicto, the “king of nuclear drugs,” is pushing precision treatment for prostate cancer into a new era of explosive growth with an almost overwhelming momentum. Novartis’ Q1 2026 report shows that the sales curve of this prostate cancer radioligand therapy continues to be steep: $280 million in its first year of launch in 2022, $980 million in 2023, $1.392 billion in 2024, and $1.994 billion for the whole of 2025, maintaining a growth rate of over 40% for three consecutive years , officially becoming the world’s first radiopharmaceutical product to break the $1 billion mark. Multinational giants, the “kings of nuclear medicine,” are making great strides in the prostate cancer field, while domestic innovative forces are also accelerating their progress . Hengrui Medicine’s self-developed PSMA-targeted nuclear medicine HRS-4357 has started Phase III clinical trials; Hansoh Pharmaceutical’s ...
- Source: drugdu
- 75
- May 25, 2026
【EXPERT Q&A】The Difference Between a Ventilator and an Oxygen Concentrator

Drugdu.com expert’s response: Although both contain the word “breathing” in their names, ventilators and oxygen concentrators are two completely different categories of medical devices that solve different problems. In one sentence: A ventilator helps you breathe — when stop working, it does the job for them. An oxygen concentrator helps you get more oxygen — your lungs still work, but the air you breathe in doesn’t contain enough oxygen, so it raises the oxygen concentration for you. Their working principles are completely different. A ventilator uses positive pressure to force gas (air or an air-oxygen mix) into your lungs, or applies pressure during exhalation to help push the air out. It replaces or assists your respiratory muscles (diaphragm, intercostal muscles) and the entire ventilation process. An oxygen concentrator, on the other hand, filters nitrogen out of the air, enriches the oxygen, and outputs high-concentration oxygen (usually above 90%). It does not participate in your breathing ...
- Source: drugdu
- 91
- May 25, 2026
Boehringer Ingelheim’s new oral drug “Zonaitinib” has been approved for a new indication in China

On May 21, Boehringer Ingelheim and Sino Biopharmaceutical jointly announced that zongertinib tablets have been approved by the National Medical Products Administration (NMPA) of China for first -line treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring HER2 ( ERBB2 ) tyrosine kinase domain activating mutations. Zongertinib is an oral HER2 tyrosine kinase inhibitor. This approval follows the NMPA’s Center for Drug Evaluation (CDE) granting the product Breakthrough Therapy designation for first-line indication and its NMPA approval for the treatment of previously treated patients in August 2025. Zonaitinib tablets are an irreversible tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 (ERBB2) while preserving wild-type EGFR , thereby helping to reduce related toxic reactions. The incidence of HER2 mutations in non-small cell lung cancer is approximately 2%-4%. These mutations are more common in women, non-smokers, patients with lung adenocarcinoma, and younger individuals. These tumors ...
- Source: drugdu
- 175
- May 22, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.